Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.

Heudel P, Frenel JS, Dalban C, Bazan F, Joly F, Arnaud A, Abdeddaim C, Chevalier-Place A, Augereau P, Pautier P, Chakiba C, You B, Lancry-Lecomte L, Garin G, Marcel V, Diaz JJ, Treilleux I, Pérol D, Fabbro M, Ray-Coquard I

Open source

DOI: 10.1001/jamaoncol.2022.1047
Published: 2022 Jul 1
Container: JAMA oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1001/jamaoncol.2022.1047,
  title = {Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.},
  author = {Heudel P and Frenel JS and Dalban C and Bazan F and Joly F and Arnaud A and Abdeddaim C and Chevalier-Place A and Augereau P and Pautier P and Chakiba C and You B and Lancry-Lecomte L and Garin G and Marcel V and Diaz JJ and Treilleux I and Pérol D and Fabbro M and Ray-Coquard I},
  year = {2022},
  journal = {JAMA oncology},
  doi = {10.1001/jamaoncol.2022.1047},
  url = {https://doi.org/10.1001/jamaoncol.2022.1047}
}

RIS

TY  - JOUR
TI  - Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.
AU  - Heudel P
AU  - Frenel JS
AU  - Dalban C
AU  - Bazan F
AU  - Joly F
AU  - Arnaud A
AU  - Abdeddaim C
AU  - Chevalier-Place A
AU  - Augereau P
AU  - Pautier P
AU  - Chakiba C
AU  - You B
AU  - Lancry-Lecomte L
AU  - Garin G
AU  - Marcel V
AU  - Diaz JJ
AU  - Treilleux I
AU  - Pérol D
AU  - Fabbro M
AU  - Ray-Coquard I
PY  - 2022
JO  - JAMA oncology
DO  - 10.1001/jamaoncol.2022.1047
UR  - https://doi.org/10.1001/jamaoncol.2022.1047
ER  -

APA

P, H., JS, F., C, D., F, B., F, J., A, A., C, A., A, C., P, A., P, P., C, C., B, Y., L, L., G, G., V, M., JJ, D., I, T., D, P., M, F., & I, R. (2022). Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.. JAMA oncology. https://doi.org/10.1001/jamaoncol.2022.1047

Source records

pubmed · retrieved 2026-11-10T12:07:36.156Z